Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer

Published:2018-10-01 Issue:10 Volume:4 Page:1344
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Autio Karen A.¹²,Dreicer Robert³,Anderson Justine¹,Garcia Jorge A.⁴,Alva Ajjai⁵,Hart Lowell L.⁶,Milowsky Matthew I.⁷,Posadas Edwin M.⁸,Ryan Charles J.⁹,Graf Ryon P.¹⁰,Dittamore Ryan¹⁰,Schreiber Nicole A.¹,Summa Jason M.¹¹,Youssoufian Hagop¹¹,Morris Michael J.¹²,Scher Howard I.¹²

Affiliation:

1. Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

2. Department of Medicine, Weill Cornell Medicine, New York, New York

3. Department of Medicine and Urology, University of Virginia School of Medicine, Charlottesville

4. Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, Ohio

5. Division of Hematology and Oncology, Department of Medicine, University of Michigan Health System, Ann Arbor

6. Florida Cancer Specialists, Fort Myers

7. Division of Hematology and Oncology, Department of Medicine, University of North Carolina, Chapel Hill

8. Division of Hematology and Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California

9. Division of Hematology and Oncology, Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco

10. Epic Sciences, Inc, San Diego, California

11. Bind Therapeutics, Inc, Cambridge, Massachusetts

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Reference31 articles.

1. Prostate-specific membrane antigen is produced in tumor-associated neovasculature.;Chang;Clin Cancer Res,1999

2. Prostate-specific membrane antigen expression in normal and malignant human tissues.;Silver;Clin Cancer Res,1997

3. 99mTc–labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer.;Vallabhajosula;J Nucl Med,2014

4. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.;Tagawa;Clin Cancer Res,2013

5. A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors.;Weber;J Immunother,2011

Cited by 180 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Navigating the nanoscale: Principles of body navigation;Nanotechnology Tools for Infection Control;2025

2. Development of CD33-Targeted Dual Drug-Loaded Nanoparticles for the Treatment of Pediatric Acute Myeloid Leukemia;Biomacromolecules;2024-09-05

3. Polyester nanoparticles delivering chemotherapeutics: Learning from the past and looking to the future to enhance their clinical impact in tumor therapy;WIREs Nanomedicine and Nanobiotechnology;2024-09

4. Artificial Intelligence: A Catalyst for Breakthroughs in Nanotechnology and Pharmaceutical Research;International Journal of Pharmaceutical Sciences and Nanotechnology(IJPSN);2024-08-15

5. Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy;Pharmaceuticals;2024-08-05